Page Sterling, APRN
Family · Johnson City, TNNPI 1104894641
Payments from drug & device makers
Across 138 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$370
- Novo Nordisk$369
- AstraZeneca$246
- Pfizer$235
- GSK$214
- Lilly USA, LLC$191
- plus $786 from 18 others
What the payments were for
- Food & beverage$2,411100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $370 |
| Novo Nordisk | 23 | $369 |
| AstraZeneca | 13 | $246 |
| Pfizer | 14 | $235 |
| GSK | 13 | $214 |
| Lilly USA, LLC | 10 | $191 |
| Astellas Pharma US Inc | 4 | $109 |
| Amgen | 7 | $105 |
| Bayer | 5 | $94 |
| Exact Sciences | 4 | $63 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $61 |
| Alnylam Pharmaceuticals Inc. | 2 | $50 |
| Boehringer Ingelheim | 3 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Sun Pharmaceutical Industries Inc. | 2 | $32 |
| Ardelyx, Inc. | 1 | $25 |
| Inogen, Inc. | 3 | $21 |
| Philips North America LLC | 1 | $20 |
| Medtronic | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$2,411 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $84,489 |
| JardianceEmpagliflozin | 67 | $68,794 |
| MounjaroTirzepatide | 39 | $49,483 |
| EliquisApixaban | 34 | $30,055 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $29,625 |
| TrulicityDulaglutide | 20 | $26,823 |
| XareltoRivaroxaban | 21 | $24,103 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 17 | $14,982 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $14,639 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $13,779 |
| JanuviaSitagliptin Phosphate | 14 | $13,312 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $12,651 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $10,869 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $10,845 |
| Spiriva RespimatTiotropium Bromide | 14 | $7,438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat | $47 | $91,21398 claims |
| Novo NordiskOzempic | $369 | $84,48980 claims |
| Lilly USA, LLCMounjaro, Trulicity | $191 | $76,30559 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta | $214 | $45,47073 claims |
| PfizerEliquis | $235 | $30,05534 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $246 | $15,51927 claims |
| AbbVieSynthroid | $370 | $2,95538 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.
Other family in Johnson City
- Rhonda BentleyJohnson City$109K
- Michelle JonesJohnson City$46K
- Rachel AndersonJohnson City$34K
- Jeffrey TaylorJohnson City$25K
- Joshua BuckJohnson City$19K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.